Geode Capital Management, LLC I Mab Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in I Mab stock. As of the latest transaction made, Geode Capital Management, LLC holds 34,347 shares of IMAB stock, worth $53,581. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,347

Previous 34,347 -0.0%

Holding current value

$53,581

Previous $65,000 3.08%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.18 - $3.06 $251 - $651	-213 Reduced 0.62%	34,347 $45,000
Q2 2023 Aug 11, 2023	SELL	$2.95 - $3.85 $613 - $800	-208 Reduced 0.6%	34,560 $103,000
Q1 2023 May 15, 2023	SELL	$3.08 - $7.39 $58,510 - $140,387	-18,997 Reduced 35.33%	34,768 $120,000
Q4 2022 Feb 13, 2023	BUY	$3.22 - $4.86 $76,813 - $115,935	23,855 Added 79.76%	53,765 $224,000
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $54,515 - $167,762	-13,595 Reduced 31.25%	29,910 $119,000

Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $1.14 Million - $2.54 Million	-137,809 Reduced 76.01%	43,505 $491,000
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $75,453 - $282,377	6,017 Added 3.43%	181,314 $2.93 Million
Q4 2021 Feb 11, 2022	BUY	$45.28 - $74.5 $823,960 - $1.36 Million	18,197 Added 11.58%	175,297 $8.25 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $1.03 Million - $1.52 Million	18,009 Added 12.95%	157,100 $11.3 Million
Q2 2021 Aug 13, 2021	BUY	$47.86 - $83.95 $6.15 Million - $10.8 Million	128,599 Added 1225.69%	139,091 $11.6 Million
Q4 2020 Feb 12, 2021	BUY	$32.94 - $47.15 $169,772 - $243,011	5,154 Added 96.55%	10,492 $494,000
Q3 2020 Nov 13, 2020	BUY	$27.46 - $47.03 $146,581 - $251,046	5,338 New	5,338 $251,000

Others Institutions Holding IMAB

# of Institutions

Shares Held

16M

Call Options Held

11.9K

Put Options Held

3.5K

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC I Mab Transaction History